Sign up
Pharma Capital

Johnson & Johnson, Imerys ordered to pay additional US$80mln in punitive damages in talc-cancer case

A New Jersey state court jury awarded the damages today, the report says
Magnifying glass on Johnson & Johnson logo
The jury has awarded a total of US$117mln in punitive and compensatory damages

Johnson & Johnson (NYSE:JNJ) and a unit of talc-mining company Imerys SA (NK:PA) were ordered to pay an additional US$80mln in punitive damages to an investment banker who claimed their talc-based products caused him to develop a deadly cancer, Reuters reported.

A New Jersey state court jury awarded the additional damages today, the report said. The decision brings the total award to $117 million. The jury last week ordered the two companies to pay $37 million in compensatory damages.

Johnson & Johnson shares were little changed at US$129.73 at 3:43 p.m.

Register here to be notified of future JNJ Company articles
View full JNJ profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.